MHC antigens and malignancy - PubMed (original) (raw)

. 1986 Aug;322(6079):502-3.

doi: 10.1038/322502a0.

• PMID: 3461283
• DOI: 10.1038/322502a0

MHC antigens and malignancy

H Festenstein et al. Nature. 1986 Aug.

No abstract available

PubMed Disclaimer

Similar articles

• Carcinogen-treated skin allografts rejected by T lymphocytes specific for class I but not class II MHC antigens.
  Halliday GM, Odling KA, Muller HK. Halliday GM, et al. Cell Immunol. 1993 Oct 15;151(2):291-9. doi: 10.1006/cimm.1993.1239. Cell Immunol. 1993. PMID: 8402936
• Influence of the H-2 and H-1 histocompatibility systems upon life span and spontaneous cancer incidences in congenic mice.
  Smith GS, Walford RL. Smith GS, et al. Birth Defects Orig Artic Ser. 1978;14(1):281-312. Birth Defects Orig Artic Ser. 1978. PMID: 415771 No abstract available.
• The seven rules of MHC restriction.
  Klein J, Marusić M, Nagy ZA. Klein J, et al. Transplant Proc. 1982 Sep;14(3):581-3. Transplant Proc. 1982. PMID: 6184862 No abstract available.
• Processed antigen and MHC molecules.
  Cohen IR, Friedman A. Cohen IR, et al. Prog Allergy. 1985;36:190-202. Prog Allergy. 1985. PMID: 3918313 Review. No abstract available.
• The dichotomy of peptide presentation by class I and class II MHC proteins.
  Urban RG, Chicz RM, Vignali DA, Strominger JL. Urban RG, et al. Chem Immunol. 1993;57:197-234. Chem Immunol. 1993. PMID: 8260088 Review. No abstract available.

Cited by

• Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
  Tambunlertchai S, Geary SM, Naguib YW, Salem AK. Tambunlertchai S, et al. AAPS J. 2023 Jun 2;25(4):57. doi: 10.1208/s12248-023-00824-3. AAPS J. 2023. PMID: 37266761
• Stem Cell Origin of Cancer: Implications of Oncogenesis Recapitulating Embryogenesis in Cancer Care.
  Tu SM, Aydin AM, Maraboyina S, Chen Z, Singh S, Gokden N, Langford T. Tu SM, et al. Cancers (Basel). 2023 Apr 27;15(9):2516. doi: 10.3390/cancers15092516. Cancers (Basel). 2023. PMID: 37173982 Free PMC article.
• The immune checkpoint molecule, VTCN1/B7-H4, guides differentiation and suppresses proinflammatory responses and MHC class I expression in an embryonic stem cell-derived model of human trophoblast.
  Zhou J, Tian Y, Qu Y, Williams M, Yuan Y, Karvas RM, Sheridan MA, Schulz LC, Ezashi T, Roberts MR, Schust DJ. Zhou J, et al. Front Endocrinol (Lausanne). 2023 Mar 16;14:1069395. doi: 10.3389/fendo.2023.1069395. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37008954 Free PMC article.
• Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment.
  Tambunlertchai S, Geary SM, Salem AK. Tambunlertchai S, et al. Pharmaceutics. 2022 Sep 29;14(10):2076. doi: 10.3390/pharmaceutics14102076. Pharmaceutics. 2022. PMID: 36297510 Free PMC article. Review.
• Macrophages as tools and targets in cancer therapy.
  Mantovani A, Allavena P, Marchesi F, Garlanda C. Mantovani A, et al. Nat Rev Drug Discov. 2022 Nov;21(11):799-820. doi: 10.1038/s41573-022-00520-5. Epub 2022 Aug 16. Nat Rev Drug Discov. 2022. PMID: 35974096 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Research Materials

  • NCI CPTC Antibody Characterization Program